NUC-7738 + pembrocromizumab在耐PD-1治疗的转移性黑皮瘤中实现了75%的疾病控制,超过了典型的无进展生存。 75% disease control achieved with NUC-7738 + pembrolizumab in metastatic melanoma resistant to PD-1 therapies, surpassing typical progression-free survival.
努卡纳公司在ESMO大会上报告了其Nuitide: 701研究的第2期研究结果,显示NUC-7738与布罗利祖马布联合治疗,在75%的转移性黑色素瘤患者中,可以控制疾病,而这些患者在此之前的PD-1治疗中已经有抗药性. NuCana plc reported positive results from its Phase 2 NuTide:701 study at the ESMO Congress, showing that NUC-7738 combined with pembrolizumab achieved disease control in 75% of patients with metastatic melanoma resistant to prior PD-1 therapies. 值得注意的是,7名病人有五个多月的无进展存活期,超过目前治疗的典型2-3个月。 Notably, seven patients had over five months of progression-free survival, surpassing the typical 2-3 months seen with current treatments. 组合还显示了一种有利的安全特征。 The combination also demonstrated a favorable safety profile. NuCana计划很快为NUC-7738制定未来发展纲要。 NuCana plans to outline future development for NUC-7738 soon.